Fesoterodine Prescription Fill Patterns and Evaluation of the YourWay Patient Support Plan for Patients With Overactive Bladder Symptoms and Physicians

References

• . Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740
   PubMed Web of Science ®Google Scholar
• . Piette JD, Beard A, Rosland AM, McHorney CA. Beliefs that influence cost-related medication non-adherence among the “haves” and “have nots” with chronic diseases. Patient Prefer Adherence. 2011;5:389–396
   PubMed Web of Science ®Google Scholar
• . Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care. 2005;11( 4 Suppl):S121–S129
   PubMed Web of Science ®Google Scholar
• . D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291–301
   PubMed Web of Science ®Google Scholar
• . Basra RK, Wagg A, Chapple C, . A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–779
   PubMed Web of Science ®Google Scholar
• . Sexton CC, Notte SM, Maroulis C, . Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–585
   PubMed Web of Science ®Google Scholar
• . Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562
   PubMed Web of Science ®Google Scholar
• . Leventhal H, Weinman J, Leventhal EA, Phillips LA. Health psychology: the search for pathways between behavior and health. Annu Rev Psychol. 2008;59:477–505
   PubMed Web of Science ®Google Scholar
• . Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant. 2004;19(12):3144–3149
   PubMed Web of Science ®Google Scholar
• . Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2
   PubMed Web of Science ®Google Scholar
• . Kumar K, Gordon C, Toescu V, . Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology (Oxford). 2008;47(5):690–697
   PubMed Web of Science ®Google Scholar
• . Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(6):837–844
   PubMed Web of Science ®Google Scholar
• . Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology. 2006;68( suppl 2 A):29–37
   PubMed Web of Science ®Google Scholar
• . Diokno AC, Sand PK, Macdiarmid S, Shah R, Armstrong RB. Perceptions and behaviours of women with bladder control problems. Fam Pract. 2006;23(5):568–577
   PubMed Web of Science ®Google Scholar
• . Smith AL, Nissim HA, Le TX, . Misconceptions and miscommunication among aging women with overactive bladder symptoms. Urology. 2011;77(1):55–59
   PubMed Web of Science ®Google Scholar
• . Benner JS, Nichol MB, Rovner ES, . Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–1282
   PubMed Web of Science ®Google Scholar
• . Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12(1):38–48
   PubMed Web of Science ®Google Scholar
• . Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q. 1988;15(2):175–183
   PubMedGoogle Scholar
• . Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84(2):191–215
   PubMed Web of Science ®Google Scholar
• . Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15( 4 Suppl):S118–S122
   PubMedGoogle Scholar
• . Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med. 2009;24(2):233–237
   PubMed Web of Science ®Google Scholar
• . Shah NR, Hirsch AG, Zacker C, . Predictors of first-fill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392–396
   PubMed Web of Science ®Google Scholar
• . Fischer MA, Stedman MR, Lii J, . Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–290
   PubMed Web of Science ®Google Scholar
• . Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology. 2006;68( 2 Suppl):9–16
   PubMed Web of Science ®Google Scholar
• . Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn. 2008;27(3):179–190
   PubMed Web of Science ®Google Scholar
• . Chapple C, Van Kerrebroeck P, Tubaro A, . Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–1212
   PubMed Web of Science ®Google Scholar
• . Nitti VW, Dmochowski R, Sand PK, . Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178(6):2488–2494
   PubMed Web of Science ®Google Scholar
• . Herschorn S, Becker D, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol. 2004;11(6):2430–2437
   PubMedGoogle Scholar
• . Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000;20(4):470–475
   PubMed Web of Science ®Google Scholar
• . Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183(3):1077–1081
   PubMed Web of Science ®Google Scholar
• . Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009;63(8):1177–1191
   PubMed Web of Science ®Google Scholar
• . Klutke CG, Burgio KL, Wyman JF, . Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol. 2009;181(6):2599–2607
   PubMed Web of Science ®Google Scholar
• . Wyman JF, Harding G, Klutke C, . Contributors to satisfaction with combined drug and behavioral therapy for overactive bladder in subjects dissatisfied with prior drug treatment. J Wound Ostomy Continence Nurs. 2010;37(2):199–205
   PubMed Web of Science ®Google Scholar
• . Chapple C, Van Kerrebroeck P, Tubaro A, . Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–1212
   PubMed Web of Science ®Google Scholar
• . Wyndaele JJ, Goldfischer ER, Morrow JD, . Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009;63(4):560–567
   PubMed Web of Science ®Google Scholar
• . Dmochowski RR, Peters KM, Morrow JD, . Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010;75(1):62–68
   PubMed Web of Science ®Google Scholar
• . Herschorn S, Swift S, Guan Z, . Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105(1):58–66
   PubMed Web of Science ®Google Scholar
• . Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011;107(9):1432–1440
   PubMed Web of Science ®Google Scholar
• . Weiss JP, Jumadilova Z, Johnson TM 2nd, . Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol. 2013;189(4):1396–1401
   PubMed Web of Science ®Google Scholar
• . Cardozo L, Hall T, Ryan J, . Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation. Int Urogynecol J. 2012;23(11):1581–1590
   PubMed Web of Science ®Google Scholar
• . Wagg A, Khullar V, Marschall-Kehrel D, . Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61(2):185–193
   PubMed Web of Science ®Google Scholar
• . Dubeau CE, Kraus SR, Griebling TL, . Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled trial. J Urol. 2014;191(2):395–404
   PubMed Web of Science ®Google Scholar